Anti-CD117 CAR T Cells Promising Immunotherapeutic Modality for AML
Generating CAR T cells against human cognate receptor CD117 may be a successful treatment for patients with AML.
Leukemia
LEUKEMIA
FEATURE
LATEST ARTICLES
Phase 2 Study of CPX-351 Results Promising in Relapsed Pediatric AML
Encouraging response rates in children with first relapse AML treated with CPX-351 followed by FLAG provide rationale for de novo AML study.
Study Links DLBCL and CLL Incidence to Race and Ethnicity, Urban Status
The incidence of DLBCL among Hispanic individuals and CLL among non-Hispanic black individuals was associated with urban status.
Novel Therapies Needed: Poor Prognosis of Patients With TP53-Mutated Myeloid Malignancies
Novel treatment options are needed to improve outcomes for patients with TP53</i-mutated myeloid neoplasms.
Gene Expression Approach Using Residual Cells Feasible for Future CLL Studies
Two extraction and amplification methods for gene expression analyses on residual leukemic cells may improve future studies when working with fewer cells.
Study Findings Support Long-Term Efficacy and Safety of Acalabrutinib in R/R CLL
Based on results of pharmacodynamics analyses, the phase 2 study protocol was amended to only include a 100 mg, twice-daily dosing of acalabrutinib.
Dexrazoxane Reduces Short-Term Anthracycline-Associated Cardiac Dysfunction in Pediatric AML
Pediatric patients with AML may benefit from dexrazoxane as a cardioprotectant during first-line anthracycline therapy.
Real-World Outcomes for Patients With CLL Differ in Community Setting
The Connect CLL Registry revealed that real-world treatment outcomes for patients with CLL who were treated in the community setting differed from trial results.
Smoking Tied to Inferior Survival in Acute Myeloid Leukemia
Smoking associated with inferior survival among patients receiving intensive chemotherapy for AML.
Higher Dose of CAR-T May Improve Efficacy in Relapsed/Refractory CLL
A higher dose of anti-CD19 CAR-T resulted in similar toxicities, but higher ORR and longer PFS, compared with a lower dose in patients with relapsed/refractory CLL.
Acalabrutinib as Potential First-Line Therapy for Chronic Lymphocytic Leukemia
Acalabrutinib, administered as monotherapy or in combination with obinutuzumab, may be an effective first-line therapy to improve outcomes in CLL.
First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL
A first-in-human, universal CAR-T therapy was tolerable and showed activity against relapsed/refractory T-ALL in a phase 1 study.
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL
A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.
MUC4 Overexpression and Prognosis in Acute Myeloid Leukemia
Increased bone marrow MUC4 expression is associated with reduced remission persistence and exacerbated survival in patients with acute myeloid leukemia.
Imbruvica Plus Rituximab Approved for Chronic Lymphocytic Leukemia
The FDA has approved the supplemental New Drug Application for Imbruvica® (ibrutinib;Janssen) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
KIR Alloreactivity, Genotype in Unrelated Donor Selection Not Significant to Pediatric AML, ALL Outcomes
Unrelated donor selection should not be based on KIR in any of the evaluated settings, study results suggest.
New Prognostic Score Predicts Likelihood of First Treatment Required for Early-Stage Chronic Lymphocytic Leukemia
A newly developed international prognostic score may be a useful clinical management tool to predict the likelihood of required treatment for patients with early-stage CLL.
Early Monitoring of Chronic Myeloid Leukemia Might Dictate TKI Switch
Lack of initial response to imatinib might indicate need to switch to dasatinib.
Features, Outcomes in Therapy-Related vs De Novo Acute Myeloid Leukemia
Clinicopathologic and genetic characteristics of therapy-related and de novo core-binding factor AML were studied in a multicenter, retrospective analysis.
Managing Pegasparaginase Toxicities in Adults With Acute Lymphoblastic Leukemia
Survival outcomes are relatively high for children with ALL but genetics, insufficient chemotherapy treatment, and the risk of relapse may factor into the reduced survival outcomes in adult patients.
Acute Myeloid Leukemia: Type of Anthracycline May Not Affect Long-Term Outcomes
Among patients with AML, the type of anthracycline received, and whether some patients undergoing stem cell transplantation have an HLA-identical donor, may not affect long-term outcomes.
CAR T-Cell Therapy Targeting CD19, 20, 22 Promising in CD19-Negative B-Lineage ALL
T cells targeting CD19/20/22 were also effective in single-cell tracking studies, and appeared as effective as CD19-targeting T cells in CD19-positive disease.
Atopy: Weighing Risk With the Possibility of Cure Using Hematopoietic Cell Transplantation
While 85% of nonatopic donors matched with nonatopic recipients remained nonatopic, 61% of atopic donors matched with atopic recipients became nonatopic after AHCT.
Patient With CLL May Have Had Longer COVID-19 Incubation Period
Compromised immune status could have effects on disease.
Real-World Trends in the Assessment of Minimum Residual Disease in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma
In recent years, the NCCN has updated its clinical practice guidelines to include MRD assessment for MM, ALL, and CLL.
Health-Related Quality of Life, Treatment Satisfaction After Ibrutinib Treament for Chronic Lymphocytic Leukemia
The investigators sought to describe HRQOL and treatment satisfaction of ibrutinib-treated patients with CLL in the real-world setting.
Newly Developed Rapid Point of Care Assay for Acute Promyelocytic Leukemia Diagnosis
Given the difficulty in definitevely diagnosing acute promyelocytic leukemia, researchers sought to develop a rapid point of care diagnostic assay.
Molecular Determinants of Venetoclax Response in Acute Myeloid Leukemia Identified
Patients with a NPM1, IDH1, IDH2, or DNMT3A mutation had a complete response or complete response with incomplete hematologic recovery rate of more than 80%.
Chronic Lymphocytic Leukemia Treatment Decision Making With Venetoclax-Based Therapy
A review of case studies that outline treatment decisions based on patient and disease characteristics.
Hairy Cell Leukemia: Cladribine With Concurrent Rituximab May Improve Outcomes
Rituximab has some single-agent activity in HCL, but there is evidence that it may eliminate MRD when used with cladribine or pentostatin.
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Evidence for Increased DNA Methylation Heterogeneity in Certain Circulating CLL Cells
In this study, epigenetic heterogeneity was not associated with the birth rate of leukemic cells.
FLAG+/-Ida Linked to Better Outcomes in Non-Favorable–Risk AML
Induction regimen FLAG+/-Ida appears to be more effective than 7+3 in patients with non-favorable risk AML, but prospective data are needed.
Tailored Approaches to Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Patients with acute myeloid leukemia with myelodysplasia-related changes diagnosed on the basis of dysplasia reported improved overall and event-free survival.
Second Hematologic Malignancy Deemed a “Rare” Event in CLL
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
Mobile Shields May Reduce Iodine-131 Exposure From Iodine Apamistamab Treatment for AML
Because lead-lined rooms are not always available, the SIERRA trial sought to establish whether mobile shields could provide a suitable alternative for reducing exposure rates.
Relapse Prevention in Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Researchers summarized risk factors for relapse in acute myeloid leukemia, as well as current and prospective treatment strategies for minimizing relapse risk.
Resequencing Gene Panels May Improve Prognostic Measurements for Chronic Lymphocytic Leukemia
Researchers found that mutated EGR2 and TP53 were significantly associated with worse progression-free survival in patients with chronic lymphocytic leukemia.
Study Calls for Unified Grading System for CAR-T Toxicities
A study found that grading systems for assessing toxicities from CAR-T therapy produced inconsistent scores, prompting a call for a more unified grading approach.
Mutations Associated With Disseminated Intravascular Coagulation in Acute Leukemia
Researchers assessed the cytogenetic characteristics of coagulopathy in patients with molecularly distinct acute leukemias.
Richter Transformation Survival in CLL Appears Better Among Treatment-Naive
Continued investigation of Richter transformation may be warranted as new CLL treatments emerge.
Radotinib May Have Similar Efficacy to Imatinib in Chronic Myeloid Leukemia
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
Epidemiologic Evidence of an Association Between Dengue Viral Infection and Leukemia
Risk of a leukemia diagnosis was found to be highest between 3 to 6 years following manifestation of symptoms associated with dengue viral infection.
Is Tisagenlecleucel for Relapsed Pediatric Acute Lymphoblastic Leukemia Cost-Effective?
Researchers assessed whether the incremental cost per quality-adjusted life-year of tisagenlecleucel matched estimated willingness-to-pay thresholds.
Machine Learning Identifies Newly Diagnosed CLL Patients at Risk for Certain Outcomes
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.
Survival Trends With Chronic Lymphocytic Leukemia Over 28 Years in the Netherlands
Relative survival rates were found to improve for all patient age groups over time, although excess mortality persisted to some degree.
Novel Heavy Metal Scoring System May Predict Survival Outcomes in Acute Myeloid Leukemia
Researchers hypothesized that imbalances of toxic and essential metals in patients with acute myeloid leukemia may be associated with poorer survival.
Acalabrutinib With Obinutuzumab May Be Safe, Effective in Chronic Lymphocytic Leukemia
Patients who were treatment-naive had an overall response rate of 95%, while patients with relapsed/refractory disease had an overall response rate of 92%.
Therapeutic Drug Monitoring of Asparaginase in Acute Lymphoblastic Leukemia
Researchers assessed whether adjusted asparaginase dosage helps reduce toxicity while maintaining sufficient asparaginase depletion in children with ALL.
Prognostic Value of Altered Signaling Pathways in Chronic Lymphocytic Leukemia
Mutations were found in 70% of patients, with 53% of patients possessing driver mutations and 17 genes showing mutations in more than 2% of patients.
Facts About Leukemia: 6 Myths You Might Encounter at Your Practice
It’s useful to be aware of misconceptions your patients might have about leukemia. We debunk 6 common myths.
Want to read more?
Please login or register first to view this content.
Next post in Leukemia
